从去年12月25日起,多家中国电商平台已经有礼来葡萄糖依赖性促胰岛素多肽(GIP)/ 胰高糖素样肽-1(GLP-1)受体激动剂替尔泊肽(商品名:穆峰达)的诊疗拿药服务。 替尔泊肽是礼来的王牌产品。据了解,减重版替尔泊肽在2024年前三季度收入30.18亿美元(41.09亿新元),与诺和诺德GLP-1药物司美格鲁肽在全球GLP-1赛道的第一梯队。 以某互联网医院商家为例,2.5mg:0.5ml*4支...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.